drugset / Trial / NCT05483400
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.
Timeline
- Start
- 2023-10-18
- Primary completion
- 2025-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 1200 mg | Intravenous |